You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Julia Karow tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb. Follow her on Twitter at @Julia_Karow.
The North Carolina State University team is working on scaling the technology further and may form a company to develop it commercially.
Several groups are developing diagnostic viral genome sequencing assays and panels, which promise high sensitivity and additional information on viral origin and spread.
The first version of the platform, which the company submitted for Emergency Use Authorization to the US FDA last week, analyzes RNA extracted from a swab.
Assays like SwabSeq, Dx-Seq, and LAMP-Seq promise to analyze tens to hundreds of thousands of samples in parallel but might be constrained by sample availability.
Replacing nasopharyngeal swabs with saliva samples or nasal swabs could increase throughput and convenience, as well as relieve reagent and equipment shortages.
The firm is looking into options for partnerships to bring a COVID-19 serology test to market, which could leverage its large installed base of instruments.
With $2.5 million in initial philanthropy funding, the consortium plans to launch several research projects and establish a data commons for storing and sharing results.
Several labs and at least one company have been working on assays that add samples directly to the PCR reaction and don't require RNA extraction, a time-consuming step.
Researchers at Mount Sinai, NYU School of Medicine, and Weill Cornell Medicine sequenced hundreds of SARS-CoV-2 genomes from NYC patients for phylogenetic analyses.
The firm plans to submit an EUA application for its quantitative Sanger sequencing COVID-19 test, which could run on hundreds of available CE instruments.
The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.
NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.
Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.